A Case of Fabry Disease, Pathologically Revealed as Focal Segmental Glomerulosclerosis.
- Author:
Hee Rin JOO
1
;
Seung Hyun SOHN
;
Hyun Kyung NAM
;
Won Suk AN
;
Seong Eun KIM
;
Ki Hyun KIM
;
Seo Hee RHA
Author Information
1. Department of Internal Medicine, Bumin Hospital, Korea.
- Publication Type:Case Report
- Keywords:
Fabry disease;
Alpha-galactosidase A;
Proteinuria
- MeSH:
Administration, Intravenous;
alpha-Galactosidase;
Angiokeratoma;
Enzyme Replacement Therapy;
Exons;
Fabry Disease*;
Glomerulosclerosis, Focal Segmental*;
Heart;
Humans;
Kidney;
Leukocytes;
Lysosomal Storage Diseases;
Male;
Nervous System;
Neuralgia;
Proteinuria;
Thiamine
- From:Korean Journal of Nephrology
2007;26(4):469-474
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Fabry disease is an X-linked recessive lysosomal storage disease that is caused by deficient activity of the lysosomal enzyme alpha-galactosidase A. This deficiency results in progressive lysosomal accumulation of glycosphingolipid with particular globotriaosylceramide which accumulates in the heart, kidneys, and the nervous system. The classic Fabry diease affects males, who typically experience an early onset of neuropathic pain, angiokeratoma, and anhydrosis or hypohydrosis. The introduction of enzyme replacement therapy necessitates early awareness of Fabry disease and knowledge of disease- related complications. We experienced a man presenting with acroparesthesia, anhydrosis and proteinuria, who had no residual alpha-galactosidase A activity on leukocytes and mutation analysis demonstrated thiamine deletion at position 1077, exon 7 of GLA gene. He was initially diagnosed as focal segmental glomerulosclerosis without electron microscopic examination three years ago. Now he is being treated with recombinant alpha-galactosidase A via intravenous administration for 1 month.
